Lisata adjourns vote on preferred stock conversion, reconvenes November 30
Stockholders approved a reverse stock split and two equity plans at the 2026 annual meeting but did not vote on converting Series C preferred stock.
SEC filing
4 stories
Stockholders approved a reverse stock split and two equity plans at the 2026 annual meeting but did not vote on converting Series C preferred stock.
SEC filing
Farrow, who serves as CFO and chief strategy officer of Tarsus Pharmaceuticals, joins Lisata's Audit Committee as the board expands to eight members.
SEC filing
A Form D filed October 2, 2026 shows Lisata sold the full offering to 20 investors with sales commissions of $2.6 million.
SEC filing
The merger, announced September 17, 2026, pairs Lisata's clinical-stage pipeline with Marea's cardioendocrine candidates and is expected to fund operations into 2028.
SEC filing